|
IQCC expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 5.30660000386263E-08 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.66400000001232E-07 |
| Normal-vs-Stage2 |
2.117900E-02 |
| Normal-vs-Stage3 |
2.47619999949045E-07 |
| Normal-vs-Stage4 |
4.66129999998621E-06 |
| Stage1-vs-Stage2 |
4.565800E-02 |
| Stage1-vs-Stage3 |
5.082000E-01 |
| Stage1-vs-Stage4 |
5.364800E-01 |
| Stage2-vs-Stage3 |
2.382300E-02 |
| Stage2-vs-Stage4 |
4.017600E-02 |
| Stage3-vs-Stage4 |
9.139200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.05230000052781E-07 |
| Normal-vs-AfricanAmerican |
1.917540E-02 |
| Normal-vs-Asian |
4.15639999999939E-05 |
| Caucasian-vs-AfricanAmerican |
2.937600E-01 |
| Caucasian-vs-Asian |
6.658800E-01 |
| AfricanAmerican-vs-Asian |
3.755000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.55319999994852E-06 |
| Normal-vs-Female |
1.06679999944959E-07 |
| Male-vs-Female |
9.761400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
4.41470004997058E-09 |
| Normal-vs-Age(41-60Yrs) |
2.48569999999892E-05 |
| Normal-vs-Age(61-80Yrs) |
6.26089999999913E-05 |
| Normal-vs-Age(81-100Yrs) |
2.532000E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.231200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.936560E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.155400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.574800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.685600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.998600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.91859999998378E-07 |
| Classical-VS-Follicular |
2.125400E-01 |
| Classical-VS-Other |
5.271600E-01 |
| Classical-VS-Normal |
1.05050000032136E-07 |
| Tall-VS-Follicular |
1.02310000005268E-06 |
| Tall-VS-Other |
8.044200E-02 |
| Tall-VS-Normal |
8.99835761458689E-13 |
| Follicular-VS-Other |
3.943000E-01 |
| Follicular-VS-Normal |
6.337800E-03 |
| Other-VS-Normal |
1.277750E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.026340E-04 |
| Normal-vs-N1 |
8.82629969112259E-10 |
| N0-vs-N1 |
1.556900E-04 |
|
|
